Literature DB >> 12222668

Reduction of plasma triglyceride level and enhancement of plasma albumin concentration by Oren-gedoku-to administration.

N Sekiya1, T Kogure, T Kita, Y Kasahara, I Sakakibara, H Goto, N Shibahara, Y Shimada, K Terasawa.   

Abstract

Oren-gedoku-to (Huanglian-Jie-Du-Tang, OGT) has been used for the treatment of cerebrovascular disease, hypertension, gastritis and liver disease in Japan. The present study was to test whether ingestion of OGT extract (TJ-15) would affect the metabolism of fatty acids and the usual antioxidant molecule (such as albumin, uric acid and bilirubin) levels in human plasma. After the administration of TJ-15, plasma total cholesterol and the triglyceride level significantly decreased, and lipoprotein lipase mass increased. Significant enhancement of plasma albumin level and reduction of the total plasma protein level resulted in an increment of the albumin/globulin ratio. Plasma fibrinogen, an independent risk factor for cerebrovascular disease, declined considerably, but the reduction was not statistically significant. The findings of this study suggest that ingestion of TJ-15 improves the microcirculation through lipid and protein metabolisms, and is useful for the treatment of cerebral vascular attack in human.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12222668     DOI: 10.1078/09447110260571724

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  2 in total

1.  Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet.

Authors:  Hong-xia Guo; Dai-hua Liu; Ying Ma; Jin-feng Liu; Ying Wang; Zhi-yan Du; Xin Wang; Jing-kang Shen; Hong-li Peng
Journal:  Acta Pharmacol Sin       Date:  2009-11       Impact factor: 6.150

2.  An Alternative Approach to Atopic Dermatitis: Part I-Case-Series Presentation.

Authors:  Hiromi Kobayashi; Kuniaki Takahashi; Nobuyuki Mizuno; Haruo Kutsuna; Masamitsu Ishii
Journal:  Evid Based Complement Alternat Med       Date:  2004-06-01       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.